Merck & Co offloads contract biomanufacturing ops to Fujifilm
This article was originally published in Scrip
Executive Summary
In an apparent move to shed a non-core business, Merck & Co has decided that it no longer wants to run its own in-house capability for the contract manufacture of biologics, although it will still have access to the operations that it has built up in this sector.
You may also be interested in...
How BARDA Locked Up COVID-19 Vaccine Manufacturing Capacity For Operation Warp Speed
US agency avoided procurement delays with sole-source awards to two medical countermeasures venture partners worth nearly $900m.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.